Julien Flament

Julien Flament

Auto-generated profile, based on publicly available information

Julien Flament

CEA, MIRCen, Fontenay-Aux-Roses, Île-de-France, 92260, FRANCE

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Stroke
Verified
Journal Article
Closed access
PDF file
RGRomain Goulay
Romain Goulay
JFJulien Flament
Julien Flament
MGMaxime Gauberti
Maxime Gauberti
MNMichael Naveau
Michael Naveau
NPNolwenn Pasquet
Nolwenn Pasquet
TGThomas Gaberel
Thomas Gaberel
Background and Purpose—: Subarachnoid hemorrhage (SAH) is a devastating form of stroke with neurological outcomes dependent on the occurrence of delayed cerebral ischemia. It has been shown in rodents that some of the mechanisms leading to delayed cerebral ischemia are related to a decreased circulation of the cerebrospinal fluid (CSF) within the brain parenchyma. Here, we evaluated the cerebral circulation of the CSF in a nonhuman primate in physiological condition and after SAH. Methods—: We first evaluated in physiological condition the circulation of the brain CSF in Macaca facicularis , using magnetic resonance imaging of the temporal DOTA-Gd distribution after its injection into the CSF. Then, animals were subjected to a minimally invasive SAH before an MRI evaluation of the impact of SAH on the brain parenchymal CSF circulation. Results—: We first demonstrate that the CSF actively penetrates the brain parenchyma. Two hours after injection, almost the entire brain is labeled by DOTA-Gd. We also show that our model of SAH in nonhuman primate displays the characteristics of SAH in humans and leads to a dramatic impairment of the brain parenchymal circulation of the CSF. Conclusions—: The CSF actively penetrates within the brain parenchyma in the gyrencephalic brain, as described for the glymphatic system in rodent. This parenchymal CSF circulation is severely impaired by SAH.

25 May 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MPMarco Palombo
Marco Palombo
CLClémence Ligneul
Clémence Ligneul
CNChloé Najac
Chloé Najac
JDJuliette Le Douce
Juliette Le Douce
JFJulien Flament
Julien Flament
JVJulien Valette
Julien Valette
Significance: Characterizing the microstructure of an organ noninvasively using molecular diffusion measurements represents a major challenge in medical imaging and life science. In this work, we propose concepts in diffusion magnetic resonance to noninvasively extract morphological properties of brain cells that are out of reach of existing neuroimaging techniques, such as diffusion-weighted MRI. We show how long-range morphology of neurons and astrocytes can affect the diffusion of cell-specific metabolites at ultra-long diffusion times and that adequate modeling strategy seems to allow extracting morphological parameters such as astrocytic and neuronal process length and complexity, opening the way to noninvasive histology of the brain. We believe that the concepts and methods introduced here may represent a significant breakthrough in neuroimaging and neurosciences.

30 January 2018 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
PDF file
HKHermes Arytto Salles Kamimura
Hermes Arytto Salles Kamimura
JFJulien Flament
Julien Flament
JVJulien Valette
Julien Valette
ACAndrea Cafarelli
Andrea Cafarelli
RBRomina Aron Badin
Romina Aron Badin
BLBenoit Larrat
Benoit Larrat
Focused ultrasound (FUS) in combination with microbubbles is capable of noninvasive, site-targeted delivery of drugs through the blood–brain barrier (BBB). Although acoustic parameters are reproducible in small animals, their control remains challenging in primates due to skull heterogeneity. This study describes a 7-T magnetic resonance (MR)-guided FUS system designed for BBB disruption in non-human primates (NHP) with a robust feedback control based on passive cavitation detection (PCD). Contrast enhanced T1-weighted MR images confirmed the BBB opening in NHP sonicated during 2 min with 500-kHz frequency, pulse length of 10 ms, and pulse repetition frequency of 5 Hz. The safe acoustic pressure range from 185 ± 22 kPa to 266 ± 4 kPa in one representative case was estimated from combining data from the acoustic beam profile with the BBB opening and hemorrhage profiles obtained from MR images. A maximum amount of MR contrast agent at focus was observed at 30 min after sonication with a relative contrast enhancement of 67% ± 15% (in comparison to that found in muscles). The feedback control based on PCD using relative spectra was shown to be robust, allowing comparisons across animals and experimental sessions. Finally, we also demonstrated that PCD can test acoustic coupling conditions, which improves the efficacy and safety of ultrasound transmission into the brain.

1 October 2016 in NeuroImage
Verified
Journal Article
Open access
JPJérémy Pépin
Jérémy Pépin
LFLaetitia Francelle
Laetitia Francelle
MSMaria-Angeles Carrillo-De Sauvage
Maria-Angeles Carrillo-De Sauvage
LLLucie de Longprez
Lucie de Longprez
PGPauline Gipchtein
Pauline Gipchtein
JFJulien Flament
Julien Flament
Huntington's disease (HD) is an inherited neurodegenerative disease characterized by motor, cognitive and psychiatric symptoms. Atrophy of the striatum has been proposed for several years as a biomarker to assess disease progression in HD gene carriers. However, it does not provide any information about the biological mechanisms linked to HD pathogenesis. Changes in brain metabolites have been also consistently seen in HD patients and animal models using Magnetic Resonance Spectroscopy (MRS), but metabolite measurements are generally limited to a single voxel. In this study, we used Chemical Exchange Saturation Transfer imaging of glutamate (gluCEST) in order to map glutamate distribution in the brain of a knock-in mouse model (Ki140CAG) with a precise anatomical resolution. We demonstrated that both heterozygous and homozygous mice with pathological CAG repeat expansion in gene encoding huntingtin exhibited an atrophy of the striatum and a significant alteration of their metabolic profile in the striatum as compared to wild type littermate controls. The striatal decrease was then confirmed by gluCEST imaging. Surprisingly, CEST imaging also revealed that the corpus callosum was the most affected structure in both genotype groups, suggesting that this structure could be highly vulnerable in HD. We evaluated for the first time gluCEST imaging as a potential biomarker of HD and demonstrated its potential for characterizing metabolic defects in neurodegenerative diseases in specific regions.

1 May 2019 in NeuroImage
Verified
Journal Article
Closed access
CLClémence Ligneul
Clémence Ligneul
MPMarco Palombo
Marco Palombo
EHEdwin Hernández-Garzón
Edwin Hernández-Garzón
MSMaría-Angeles Carrillo-De Sauvage
María-Angeles Carrillo-De Sauvage
JFJulien Flament
Julien Flament
JVJulien Valette
Julien Valette

17 March 2022 in Brain
Verified
Journal Article
Closed access
LALaurene Abjean
Laurene Abjean
LHLucile Ben Haim
Lucile Ben Haim
MRMiriam Riquelme-Perez
Miriam Riquelme-Perez
PGPauline Gipchtein
Pauline Gipchtein
CDCéline Derbois
Céline Derbois
CECarole Escartin
Carole Escartin
Huntington’s disease is a fatal neurodegenerative disease characterized by striatal neurodegeneration, aggregation of mutant Huntingtin and the presence of reactive astrocytes. Astrocytes are important partners for neurons and engage in a specific reactive response in Huntington’s disease that involves morphological, molecular and functional changes. How reactive astrocytes contribute to Huntington’s disease is still an open question, especially because their reactive state is poorly reproduced in experimental mouse models. Here, we show that the JAK2-STAT3 pathway, a central cascade controlling astrocyte reactive response, is activated in the putamen of Huntington’s disease patients. Selective activation of this cascade in astrocytes through viral gene transfer reduces the number and size of mutant Huntingtin aggregates in neurons and improves neuronal defects in two complementary mouse models of Huntington’s disease. It also reduces striatal atrophy and increases glutamate levels, two central clinical outcomes measured by non-invasive magnetic resonance imaging. Moreover, astrocyte-specific transcriptomic analysis shows that activation of the JAK2-STAT3 pathway in astrocytes coordinates a transcriptional program that increases their intrinsic proteolytic capacity, through the lysosomal and ubiquitin-proteasome degradation systems. This pathway also enhances their production and exosomal release of the co-chaperone DNAJB1, which contributes to mutant Huntingtin clearance in neurons. Together, our results show that the JAK2-STAT3 pathway controls a beneficial proteostasis response in reactive astrocytes in Huntington’s disease, which involves bi-directional signalling with neurons to reduce mutant Huntingtin aggregation, eventually improving disease outcomes.